Dr Reddy's Laboratories Ltd banner

Dr Reddy's Laboratories Ltd
SWB:RDDA

Watchlist Manager
Dr Reddy's Laboratories Ltd Logo
Dr Reddy's Laboratories Ltd
SWB:RDDA
Watchlist
Price: 11.7 EUR
Market Cap: €1.9B

Net Margin

16.1%
Current
Declining
by 1.9%
vs 3-y average of 18%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16.1%
=
Net Income
₹55.7B
/
Revenue
₹346.8B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16.1%
=
Net Income
€55.7B
/
Revenue
₹346.8B

Peer Comparison

Country Company Market Cap Net
Margin
IN
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
1T INR
Loading...
ZA
Aspen Pharmacare Holdings Ltd
JSE:APN
48.4B ZAR
Loading...
US
Eli Lilly and Co
NYSE:LLY
964.4B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
572.6B USD
Loading...
CH
Roche Holding AG
SIX:ROG
284.3B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
297.7B USD
Loading...
CH
Novartis AG
SIX:NOVN
228.8B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
217.7B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
151.1B USD
Loading...

Market Distribution

Higher than 79% of companies in India
Percentile
79th
Based on 5 531 companies
79th percentile
16.1%
Low
-305 007.7% — 2.1%
Typical Range
2.1% — 11.6%
High
11.6% — 1 221 633.3%
Distribution Statistics
India
Min -305 007.7%
30th Percentile 2.1%
Median 5.8%
70th Percentile 11.6%
Max 1 221 633.3%

Dr Reddy's Laboratories Ltd
Glance View

In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.

RDDA Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
16.1%
=
Net Income
₹55.7B
/
Revenue
₹346.8B
What is Dr Reddy's Laboratories Ltd's current Net Margin?

The current Net Margin for Dr Reddy's Laboratories Ltd is 16.1%, which is below its 3-year median of 18%.

How has Net Margin changed over time?

Over the last 3 years, Dr Reddy's Laboratories Ltd’s Net Margin has increased from 15.3% to 16.1%. During this period, it reached a low of 15.3% on Dec 1, 2022 and a high of 19.9% on Mar 31, 2024.

Back to Top